Anhui Fengyuan Pharmaceutical (000153.SZ) subsidiary's tirofiban hydrochloride API approved for marketing

Anhui Fengyuan Pharmaceutical (000153.SZ) announced that recently, its wholly-owned subsidiary Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd. received the "Chemical API Marketing Application Approval Notice" for tirofiban hydrochloride issued by the National Medical Products Administration. Tirofiban hydrochloride is a reversible antagonist of fibrinogen binding to the platelet surface GPIIb/IIIa receptor. Intravenous administration can inhibit platelet aggregation and is used in adult patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) to reduce the risk of early ischemic events such as myocardial infarction; it can also be used in patients with ST-segment elevation acute myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) to reduce the occurrence of major cardiovascular events.